Saraya Post / a medicine to treat diabetes has an anti-aging potential

Investor Ariel Buller thinks he has discovered a way to live longer and healthier, at a cost not exceeding $ 2 a month. Metformin has been given to millions of diabetics to reduce their blood sugar, but in recent years, Buller and a growing number of Silicon Valley residents have started using low-cost parabolic drugs in hopes of extending their blood sugar levels. life. The medical community is not convinced of the effect of anti-aging medications and may have the opportunity to conduct research to help them make an informed decision, which comes with metformin in the field of anti-aging treatments . The drug has long been used to treat diabetes for decades, but researchers are beginning to explore its other health benefits. A study conducted in 2014 showed that diabetic patients taking the drug lived longer than the comparator group, which led the researchers to conclude that metformin could also be beneficial for non-diabetic patients. Another study concluded that the drug was a cause of longevity in mice.

These studies, in addition to other studies, have led Boler and his colleagues in Silicon Valley to buy metformin recipes, which cost about five cents a pill. "Although I am not exposed to diabetes, I took the drug, I tried it and I quickly felt a better metabolism in my body," Zhen Chu told CNBC.

Unfortunately, it is not possible to determine the effectiveness of the drug or the effect of the fake drug because research on the effects of anti-aging drugs on humans is insufficient.

This medication has potential side effects ranging from diarrhea and hypoglycemia to abdominal pain and lactic acidosis, which means that it can cause more harm than harm.

This led the physician, Greg Borel, to tell CNBC that he had advised his non-diabetic patients to wait for further studies to come before buying the drug. According to CNBC sources, pharmaceutical companies have allocated a small budget to research other uses of low-cost equivalent drugs, which means waiting longer for patients to wait for the recommendations they trust.